reMYND

Foundation date

07/02/2002

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

reMYND actively drives the development of disease modifying treatments against Alzheimer’s disease (AD), Parkinson’s disease (PD), and diabetes, either as a Contract Research Organisation (CRO) or through its own drug discovery & development (DDD).

Upcoming events

Latest news

  • Cerba Research & Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture

    9 hours ago

  • Novalis Biotech invests in Rarity Bioscience's ultra sensitive genomics technology

    1 day ago

  • Fat creates an ideal environment for metastatic breast tumors

    1 day ago

Jobs by reMYND